Navigation Links
MedAvante Central Ratings Selected For Cerecor Investigational MDD Study

HAMILTON, N.J., Dec. 2, 2013 /PRNewswire/ -- MedAvante, Inc., the world's leading provider of centralized assessments and monitoring in clinical trials of treatments for central nervous system (CNS) disorders, announced that biopharmaceutical company Cerecor Inc. will use MedAvante Central Ratings in the phase 2 clinical study of CERC-301, an investigational drug intended for the adjunctive treatment of subjects with major depressive disorder (MDD) who have not adequately responded to their current therapy and report recent suicidal ideation.

"A new treatment with potential for rapid onset of action for severely depressed, treatment resistant patients is urgently needed," said James Vornov, MD, PhD, Cerecor SVP, Clinical Development and Regulatory Affairs.

"In this Phase 2 study of CERC-301, an oral, selective NMDA receptor subunit 2B (NR2B) antagonist, we will use the blinded, independent MedAvante Central Raters to maximize signal detection through objective and standardized outcome measurement," he said.

Central Ratings assessments of study subjects at investigative research sites will be conducted by experienced and continuously trained MedAvante clinicians, confirming symptom severity prior to randomization and administering the trial's primary endpoint measure.

"MedAvante has unique clinical and operational expertise and technology to handle the sensitive requirements of our study," said Dr. Vornov.  "They utilize a robust process to standardize the assessments and ensure that the Central Raters are fully blinded to protocol and visit history."

"MedAvante Central Ratings attack the root causes of the intractable problem of a high percentage of CNS trials failing to determine conclusive outcomes," said Paul M. Gilbert, co-founder and CEO of MedAvante.  "Because we provide a smaller number of trained clinical raters to perform assessments in place of different raters at every site, we can minimize variability of study data and avoid perception biases which can increase placebo response and reduce observed drug effect," he said.  "We are proud to bring these capabilities to the Cerecor study."

About MedAvante, Inc.

MedAvante is the leading global provider of centralized expert psychiatric and neurocognition rating and monitoring services to the pharmaceutical, biotechnology and medical device industries.  MedAvante central trial services help sponsors enhance assay sensitivity for increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. Supported by operational teams in the US, Germany, Russia and Japan, MedAvante clinicians located in 31 countries and speaking 26 languages deliver Central Trial Services in 41 countries worldwide.
For more information, please visit

About Cerecor Inc.

Cerecor Inc. is a privately held clinical stage biopharmaceutical company developing prescription pharmaceuticals that work in the human nervous system and which address the needs of underserved patient segments of major diseases.  We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders.

SOURCE MedAvante, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. A molecule central to diabetes is uncovered
3. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
4. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
5. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
6. ‘Timely’ new undergrad program in photonics at University of Central Florida applauded by SPIE
7. Site Quality Management to Optimize Risk-Based and Centralized Monitoring, New Life Science Webinar Hosted by Xtalks
8. Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at
9. Endpoint Based Protocol Development: A Central Laboratory Perspective + Microbiology Case Study, New Life Science Webinar Hosted by Xtalks
10. Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sullefficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
11. Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
Post Your Comments:
(Date:11/30/2015)... 1, 2015  An interventional radiology technique shows promise for ... results of a study being presented today at the annual ... (RSNA). --> ... by interventional radiologists as a way to stop bleeding in ... a means of treating obesity is new. Mubin ...
(Date:11/30/2015)... Mass. , Nov. 30, 2015 ... HART ), a biotechnology company developing bioengineered organ ... received written notification from The NASDAQ Stock Market ... bid price requirements. The letter noted that as ... HART,s common stock having exceeded $1.00 per share ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Champions Oncology, ... solutions and services to personalize the development and use ... , Chief Executive Officer, will be presenting at the ... at 4:30pm Pacific Standard Time (PST).  The conference, held ... Los Angeles, CA , will feature 200 ...
(Date:11/30/2015)... 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage ... will present at two upcoming investor conferences. Aytu is ... virtual conference, to be held December 3, 2015, and ... held December 2 nd & 3 rd , ... streamed live via webcast. Josh Disbrow , ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/27/2015)... Oct. 27, 2015 In the present market ... concern for various industry verticals such as banking, healthcare, ... the growing demand for secure & simplified access control ... such as hacking of bank accounts, misuse of users, ... such as PC,s, laptops, and smartphones are expected to ...
(Date:10/26/2015)... Calif. , Oct. 26, 2015  Delta ID ... biometric authentication to mobile and PC devices, announced its ... smartphone, the arrows NX F-02H launched by NTT DOCOMO, ... NX F-02H is the second smartphone to include iris ... technology in ARROWS NX F-04G in May 2015, world,s ...
Breaking Biology News(10 mins):